However, immunotherapy as a first-line therapy was abandoned in advanced NSCLC harboring the EGFR mutation in many clinical trials [37], despite a few positive results in IMpower15030 and ATLANTIC31. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.